Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 3
1981 7
1982 4
1983 7
1984 6
1985 8
1986 15
1987 11
1988 9
1989 10
1990 6
1991 4
1992 11
1993 4
1994 7
1995 9
1996 5
1997 6
1998 3
1999 5
2000 5
2001 5
2002 6
2003 3
2005 3
2006 2
2007 2
2009 1
2010 1
2011 1
2012 7
2013 3
2015 1
2017 1
2018 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Results by year

Filters applied: . Clear all
Page 1
[Acute myeloid leukemia of the elderly: recent progresses in therapy].
Yamauchi T. Yamauchi T. Rinsho Ketsueki. 2018;59(6):735-740. doi: 10.11406/rinketsu.59.735. Rinsho Ketsueki. 2018. PMID: 29973453 Review. Japanese.
AML score may suggest the appropriateness of the use of intensive chemotherapy. When intensive chemotherapy is tolerable, enocitabine or cytarabine + daunorubicin is used as remission induction chemotherapy. ...
AML score may suggest the appropriateness of the use of intensive chemotherapy. When intensive chemotherapy is tolerable, enocitabine …
Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study.
Ito Y, Wakita A, Takada S, Mihara M, Gotoh M, Ohyashiki K, Ohtake S, Miyawaki S, Ohnishi K, Naoe T. Ito Y, et al. Int J Hematol. 2012 Oct;96(4):485-91. doi: 10.1007/s12185-012-1165-z. Epub 2012 Sep 6. Int J Hematol. 2012. PMID: 22956429 Clinical Trial.
We conducted a phase 1 study of a combination of gemtuzumab ozogamicin (GO) plus conventional chemotherapy in elderly patients ( 65 years old) with relapsed or refractory CD33-positive acute myeloid leukemia (AML). Patients received a standard dose of enocitabine (200 mg/m …
We conducted a phase 1 study of a combination of gemtuzumab ozogamicin (GO) plus conventional chemotherapy in elderly patients ( 65 years ol …
Clinical pharmacokinetics of cytarabine formulations.
Hamada A, Kawaguchi T, Nakano M. Hamada A, et al. Clin Pharmacokinet. 2002;41(10):705-18. doi: 10.2165/00003088-200241100-00002. Clin Pharmacokinet. 2002. PMID: 12162758 Review.
Cytarabine derivatives have shown promise in vitro and in animal models. For example, ancitabine (cyclocytidine), enocitabine and cytarabine ocfosfate have been used clinically in Japan. ...
Cytarabine derivatives have shown promise in vitro and in animal models. For example, ancitabine (cyclocytidine), enocitabine and cyt …
[Response-oriented salvage chemotherapy with mitoxantrone, etoposide and enocitabine for previously treated acute myeloid leukemia. Tohoku Leukemia Study Group].
Chubachi A, Kuriya S, Narigasawa Y, Meguro K, Endo K, Takami H, Sato S, Sasaki H, Shiga T, Maruyama Y, et al. Chubachi A, et al. Gan To Kagaku Ryoho. 1995 Dec;22(14):2101-6. Gan To Kagaku Ryoho. 1995. PMID: 8607622 Clinical Trial. Japanese.
Twenty-two patients with previously treated acute myeloid leukemia (AML) received salvage chemotherapy with mitoxantrone, 5 mg/m2/d on days 1 to 3, etoposide, 70 mg/m2/d on days 1 to 5, and enocitabine, 170 mg/m2/d on days 1 to 7 (BHAC-ME). Additional mitoxantrone, etoposi …
Twenty-two patients with previously treated acute myeloid leukemia (AML) received salvage chemotherapy with mitoxantrone, 5 mg/m2/d on days …
[Cytarabine].
Ota K. Ota K. Gan To Kagaku Ryoho. 1987 Oct;14(10):2983-7. Gan To Kagaku Ryoho. 1987. PMID: 3478003 Japanese.
On the other hand, in the development of its derivertive compounds ancitabine or enocitabine (BH-AC) were induced to a treatment of acute myelogenous leukemia. ...
On the other hand, in the development of its derivertive compounds ancitabine or enocitabine (BH-AC) were induced to a treatment of a …
[Cytidine].
Terui Y. Terui Y. Nihon Rinsho. 2015 Feb;73 Suppl 2:159-61. Nihon Rinsho. 2015. PMID: 25831743 Japanese. No abstract available.
[Allergic reaction against an emulsifier, HCO-60, contained in multamin and enocitabine].
Tatetsu H, Asou N, Nakamura M, Koh Y, Tajiri T, Matsuno F, Horikawa K, Yonemura Y, Mitsuya H. Tatetsu H, et al. Rinsho Ketsueki. 2003 Jul;44(7):471-3. Rinsho Ketsueki. 2003. PMID: 12931567 Japanese.
We report two cases of an allergic reaction to HCO-60, which is used as an emulsifien for Multamin and enocitabine. A 55-year-old woman with M 4 Eo developed a high fever, urticaria and erythema after induction chemotherapy. ...A 51-year-old woman with L 2 developed erythe …
We report two cases of an allergic reaction to HCO-60, which is used as an emulsifien for Multamin and enocitabine. A 55-year-old wom …
Long-term third chronic phase of chronic myelogenous leukemia maintained by interferon-alpha and methotrexate.
Kanda Y, Chiba S, Honda H, Hirai H, Yazaki Y. Kanda Y, et al. Leuk Lymphoma. 1999 Mar;33(1-2):193-7. doi: 10.3109/10428199909093742. Leuk Lymphoma. 1999. PMID: 10194138 Review.
The administration of interferon-alpha (IFN-alpha) alone as maintenance therapy was incapable of preventing BC, which occurred twice in the first 2 years after the diagnosis of CML. Intensive chemotherapy using enocitabine, mitoxantrone, and etoposide was effective to indu …
The administration of interferon-alpha (IFN-alpha) alone as maintenance therapy was incapable of preventing BC, which occurred twice in the …
179 results